Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: Pembrolizumab 25 mg/ml|DRUG: Paclitaxel injection
Sponsor: UNICANCER
Collaborators: MSD France|Vall d'Hebron Institute of Oncology|SOLTI Breast Cancer Research Group